<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87515">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02131051</url>
  </required_header>
  <id_info>
    <org_study_id>REP-85</org_study_id>
    <nct_id>NCT02131051</nct_id>
  </id_info>
  <brief_title>Application of Ectoine Containing Nasal Spray and Eye Drops in Patients With Allergic Rhinitis</brief_title>
  <official_title>Non-interventional Study: Application of Ectoin® Rhinitis Nasal Spray and Eye Drops in Patients With Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bitop AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bitop AG</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a comparative, open label, parallel group, non interventional study to further
      demonstrate the effectiveness and tolerability of Ectoin Allergy Nasal Spray and Eye drops.
      In addition the effectiveness and safety shall be compared to Azelastine containing nasal
      Sprays and Eye drops. The patient applied Ectoin® Rhinitis Nasal Spray / Eye drops or takes
      Azelastine nasals spray and eye drops according to the instructions for use. The observation
      takes place over a period of 7 days. Response to treatment is recorded at day 7 by the
      physician and in daily by the patient in a dairy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in primary allergic symptoms symptoms</measure>
    <time_frame>Day1, Day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in the primary allergic nasal and ophthalmic symptoms:
Degree of nasal breathing impairment, Rhinorrhea, Frequency of sneezing, Nasal itching,Eye itching, Watery eyes, Conjunctivitis score (eye redness)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Palatal itching score</measure>
    <time_frame>day 1 and day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy and tolerability assessment by the patients</measure>
    <time_frame>day1 and day 7</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients assess the efficacy and tolerability separately based on a general  an Scale from 0 to 8</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">48</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Azelastine group</arm_group_label>
    <description>Azelastine nasal spray Azelastine eye drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ectoin group</arm_group_label>
    <description>Ectoin Allergy Nasal Spray Ectoin Allergy Eye Drops</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female patients

          -  aged 18-70 years

          -  Patients with proven allergy and acute symptoms in nose and eye which are treated
             with Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops or Azelastine Nasal
             Spray and Azelastine Eye Drops during the observational period

        Exclusion Criteria:

          -  pregnancy and nursing women,

          -  drug addicts and persons unable to give consent to study participation,

          -  patients with intolerance against ingredients of any of the study treatments,

          -  previous eye or nose surgery,

          -  concomitant treatment with anti-allergic drugs, and

          -  diseases which might influence the output of the study according to the physicians'
             judgment.

          -  contra indications according to the label
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Sonnemann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HNO Praxis Elmshorn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HNO Praxis Elmshorn</name>
      <address>
        <city>Elmshorn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>April 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ectoine</keyword>
  <keyword>allergic rhinitis</keyword>
  <keyword>bitop</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
